Skip to main content

Table 1 Patient characteristics

From: Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months

Patients (n)

8

Age (years)

47.0 ± 9.7

Sex ratio (M/F)

5/3

Smokers/nonsmokers

1/7

Body mass index

23.8 ± 3.1

Total plasma IgE (kU/L)

309.4 ± 218.2

Forced expiratory volume in the first second

52% pred ± 14%

Asthma control test score

11.3 ± 2.8

  1. Data are expressed as mean ± SEM